CN101797241B - 包含s1p受体激动剂和糖醇的固体药物组合物 - Google Patents

包含s1p受体激动剂和糖醇的固体药物组合物 Download PDF

Info

Publication number
CN101797241B
CN101797241B CN2010101213007A CN201010121300A CN101797241B CN 101797241 B CN101797241 B CN 101797241B CN 2010101213007 A CN2010101213007 A CN 2010101213007A CN 201010121300 A CN201010121300 A CN 201010121300A CN 101797241 B CN101797241 B CN 101797241B
Authority
CN
China
Prior art keywords
sugar alcohol
methods
mixture
receptor stimulating
stimulating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2010101213007A
Other languages
English (en)
Chinese (zh)
Other versions
CN101797241A (zh
Inventor
大村朋幸
M·普迪派迪
A·E·罗伊斯
C·吕埃格尔
佐佐木正喜
田村德裕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Tanabe Pharma Corp
Original Assignee
Novartis AG
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101797241(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG, Mitsubishi Pharma Corp filed Critical Novartis AG
Publication of CN101797241A publication Critical patent/CN101797241A/zh
Application granted granted Critical
Publication of CN101797241B publication Critical patent/CN101797241B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN2010101213007A 2003-04-08 2004-04-06 包含s1p受体激动剂和糖醇的固体药物组合物 Expired - Lifetime CN101797241B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08
US60/461,215 2003-04-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2004800092370A Division CN1767819B (zh) 2003-04-08 2004-04-06 包含s1p受体激动剂和糖醇的固体药物组合物

Publications (2)

Publication Number Publication Date
CN101797241A CN101797241A (zh) 2010-08-11
CN101797241B true CN101797241B (zh) 2013-03-27

Family

ID=32326722

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010101213007A Expired - Lifetime CN101797241B (zh) 2003-04-08 2004-04-06 包含s1p受体激动剂和糖醇的固体药物组合物
CN2004800092370A Expired - Lifetime CN1767819B (zh) 2003-04-08 2004-04-06 包含s1p受体激动剂和糖醇的固体药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2004800092370A Expired - Lifetime CN1767819B (zh) 2003-04-08 2004-04-06 包含s1p受体激动剂和糖醇的固体药物组合物

Country Status (41)

Country Link
US (11) US20060275357A1 (https=)
EP (5) EP2316431B1 (https=)
JP (3) JP5495467B2 (https=)
KR (3) KR20050121712A (https=)
CN (2) CN101797241B (https=)
AR (3) AR043987A1 (https=)
AT (3) AT501681B1 (https=)
AU (1) AU2004228929B2 (https=)
BE (2) BE1015972A5 (https=)
BR (1) BRPI0409250B8 (https=)
CA (2) CA2521325C (https=)
CL (2) CL2004000745A1 (https=)
CY (3) CY1110260T1 (https=)
DE (4) DE122011100047I1 (https=)
DK (2) DK1613288T3 (https=)
EC (1) ECSP056090A (https=)
ES (3) ES2320767T3 (https=)
FR (2) FR2854073B1 (https=)
GB (1) GB2400318B (https=)
GR (1) GR1005052B (https=)
HR (3) HRP20100601B1 (https=)
HU (2) HUE028247T2 (https=)
IL (3) IL170888A (https=)
IS (2) IS2682B (https=)
IT (1) ITMI20040682A1 (https=)
LU (1) LU91867I2 (https=)
MA (1) MA27729A1 (https=)
MX (1) MXPA05010860A (https=)
MY (1) MY141249A (https=)
NO (4) NO329332B1 (https=)
NZ (3) NZ586280A (https=)
PE (5) PE20130200A1 (https=)
PL (2) PL1613288T3 (https=)
PT (1) PT1613288E (https=)
RU (5) RU2358716C2 (https=)
SG (1) SG175449A1 (https=)
SI (2) SI2316431T1 (https=)
TN (1) TNSN05256A1 (https=)
TW (1) TWI332847B (https=)
WO (1) WO2004089341A1 (https=)
ZA (1) ZA200507394B (https=)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1773307T3 (pl) * 2004-07-30 2015-03-31 Novartis Ag Preparaty 2-amino-1,3-propanodioli i ich analogów
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
ES2529724T3 (es) * 2005-09-09 2015-02-25 Novartis Ag Tratamiento de enfermedades autoinmunes
MY171061A (en) 2005-11-09 2019-09-24 Onyx Therapeutics Inc Compounds for enzyme inhibition
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
HUE046441T2 (hu) * 2006-09-26 2020-02-28 Novartis Ag S1P modulátort tartalmazó gyógyászati készítmények
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
NZ597109A (en) * 2007-03-29 2013-01-25 Daiichi Sankyo Co Ltd Tablet composition having favorable dissolution property useful as an anticoagulant
KR20170125413A (ko) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
EP3733161A1 (en) * 2007-10-12 2020-11-04 Novartis AG Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
PL2278960T5 (pl) 2008-03-17 2020-06-29 Actelion Pharmaceuticals Ltd. Schemat dawkowania dla selektywnego agonisty receptora sip1
JP2011525189A (ja) 2008-06-20 2011-09-15 ノバルティス アーゲー 多発性硬化症を治療するための小児科の組成物
BRPI0914164B1 (pt) * 2008-06-20 2019-04-30 Merck Patent Gmbh Comistura para produção de comprimidos de desintegração rápida em um processo de formação de comprimido direto, seus usos, e formulações de comprimido
WO2010025796A1 (en) * 2008-09-04 2010-03-11 Cargill Incorporated Tabletting of ervthritol
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
JP2012508215A (ja) 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
AU2013100531B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
PT2356090T (pt) * 2008-11-11 2017-10-16 Novartis Ag Formas cristalinas de fingolimod, hcl
SI2371830T1 (sl) 2008-12-17 2014-01-31 Daiichi Sankyo Company, Limited Postopek za pridobivanje diaminskih derivatov
EP2383272A4 (en) 2009-01-13 2012-07-25 Daiichi Sankyo Co Ltd ACTIVE BLOOD CREATION FACTOR HEMMER
WO2010104078A1 (ja) 2009-03-10 2010-09-16 第一三共株式会社 ジアミン誘導体の製造方法
WO2010104106A1 (ja) 2009-03-13 2010-09-16 第一三共株式会社 光学活性なジアミン誘導体の製造方法
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
MY155256A (en) * 2009-06-18 2015-09-30 Daiichi Sankyo Co Ltd Pharmaceutical composition having improved solubility
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
EP2542238B1 (en) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
CN102791719B (zh) 2010-03-19 2015-07-29 第一三共株式会社 二胺衍生物的晶体及其制备方法
JP5390014B2 (ja) 2010-03-19 2014-01-15 第一三共株式会社 抗凝固剤の溶出改善方法
EA201291095A1 (ru) * 2010-04-22 2013-04-30 Рациофарм Гмбх Способ получения пероральной лекарственной формы, содержащей финголимод
CA2804262C (en) 2010-07-02 2016-04-05 Daiichi Sankyo Company, Limited Process for preparation of optically active diamine derivative salt
WO2012070059A1 (en) 2010-11-25 2012-05-31 Shilpa Medicare Limited Fingolimod polymorphs and their processes
JP6111202B2 (ja) 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
NO2665471T3 (https=) 2011-01-19 2018-05-26
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
US9186333B2 (en) * 2011-08-01 2015-11-17 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions of fingolimod
ES2673182T3 (es) 2011-08-10 2018-06-20 Daiichi Sankyo Company, Limited Composición farmacéutica que contiene un derivado de diamina
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
CN109432073A (zh) 2013-01-08 2019-03-08 帕萨罗杰卡有限公司 Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
WO2014175287A1 (ja) * 2013-04-26 2014-10-30 国立大学法人 京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
WO2013190151A1 (en) * 2013-05-13 2013-12-27 Synthon B.V. Pharmaceutical composition comprising fingolimod
EP3027174B1 (en) 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2016026461A1 (en) * 2014-08-22 2016-02-25 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
EP3247341A4 (en) * 2015-01-20 2018-12-19 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
US11298412B2 (en) 2020-07-16 2022-04-12 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection
AU2022214268A1 (en) * 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators
WO2022162409A1 (en) * 2021-01-28 2022-08-04 Priothera Sas Methods of treatment with s1p receptor modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
CN1259117A (zh) * 1997-04-04 2000-07-05 吉富制药株式会社 2－氨基丙烷－1,3－二醇化合物、其作为医药的用途及其合成中间体
EP1195165A1 (en) * 1999-07-12 2002-04-10 Ono Pharmaceutical Co., Ltd. Fibrosis inhibitors containing as the active ingredient sphingosine-1-phosphate receptor agonist or sphingosine-1-phosphate

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
DE69321823T2 (de) 1992-10-21 1999-06-02 Taito Co., Ltd., Tokio/Tokyo 2-amino-1, 3- propandiolverbindung und immunosuppressium
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
WO1997024112A1 (en) 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. External preparation
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP2002241272A (ja) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
KR20000075745A (ko) * 1997-02-27 2000-12-26 가마후라 아키오 의약 조성물
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
CN1328387C (zh) 2000-07-13 2007-07-25 三共株式会社 氨基醇衍生物
EP1315735A4 (en) 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory compounds
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
CA2442178A1 (en) 2001-03-26 2002-10-03 Novartis Ag 2-amino-propanol derivatives
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
EP1424078A4 (en) 2001-09-04 2009-03-25 Ono Pharmaceutical Co RESPIRATORY DISEASE MEDICINES COMPRISING A SPHINGOSINE-1-PHOSPHATE RECEPTOR REGULATING AGENT
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
DE60235900D1 (de) 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
WO2003061567A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
JP4430941B2 (ja) 2002-01-18 2010-03-10 メルク エンド カムパニー インコーポレーテッド Ｅｄｇ受容体作動薬
US7781617B2 (en) * 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
CN1259117A (zh) * 1997-04-04 2000-07-05 吉富制药株式会社 2－氨基丙烷－1,3－二醇化合物、其作为医药的用途及其合成中间体
EP1195165A1 (en) * 1999-07-12 2002-04-10 Ono Pharmaceutical Co., Ltd. Fibrosis inhibitors containing as the active ingredient sphingosine-1-phosphate receptor agonist or sphingosine-1-phosphate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘极健.甘露醇的应用和生产.《化学工程师》.2000,(第77期),第40-43页. *

Also Published As

Publication number Publication date
DK2316431T3 (en) 2016-01-11
LU91867I9 (https=) 2019-01-03
US20200237690A1 (en) 2020-07-30
CA2707750A1 (en) 2004-10-21
NO334116B1 (no) 2013-12-16
DE202004021680U1 (de) 2010-04-22
US8324283B2 (en) 2012-12-04
DE122011100047I1 (de) 2011-12-15
TNSN05256A1 (en) 2007-07-10
BRPI0409250B1 (pt) 2017-07-11
NO20131287L (no) 2006-01-09
US20220031609A1 (en) 2022-02-03
IL197578A0 (en) 2011-07-31
MY141249A (en) 2010-03-31
KR101367574B1 (ko) 2014-02-25
US20110105620A1 (en) 2011-05-05
DK1613288T3 (da) 2009-03-23
FR11C0036I2 (fr) 2023-12-29
HRP20050886B1 (en) 2011-01-31
GR20040100121A (el) 2004-12-17
JP5543298B2 (ja) 2014-07-09
US20140255497A1 (en) 2014-09-11
KR20050121712A (ko) 2005-12-27
ATE414508T1 (de) 2008-12-15
RU2475236C2 (ru) 2013-02-20
HK1155647A1 (en) 2012-05-25
RU2005134173A (ru) 2006-09-10
JP2004307506A (ja) 2004-11-04
NZ586280A (en) 2011-12-22
BE2011C030I2 (https=) 2023-03-07
DE102004016947A1 (de) 2004-10-21
EP2008650A3 (en) 2011-04-27
EP2316431B1 (en) 2015-09-30
AT501681A1 (de) 2006-10-15
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
US20130108675A1 (en) 2013-05-02
JP2011006461A (ja) 2011-01-13
US20080311188A1 (en) 2008-12-18
NO2011016I2 (no) 2012-08-27
FR2854073A1 (fr) 2004-10-29
EP2319502A1 (en) 2011-05-11
US20060275357A1 (en) 2006-12-07
PE20090743A1 (es) 2009-07-17
ZA200507394B (en) 2007-03-28
MA27729A1 (fr) 2006-01-02
CA2521325C (en) 2010-09-14
RU2010146697A (ru) 2012-05-27
US20090203798A1 (en) 2009-08-13
HRP20100601A2 (hr) 2011-03-31
SG175449A1 (en) 2011-11-28
CY2011013I1 (el) 2014-04-09
WO2004089341A1 (en) 2004-10-21
HRP20050886A2 (en) 2006-11-30
NO20100250L (no) 2006-01-09
JP2013177404A (ja) 2013-09-09
PL1613288T3 (pl) 2009-07-31
CN1767819A (zh) 2006-05-03
ES2228282B1 (es) 2006-02-16
NO335120B1 (no) 2014-09-22
KR20120101148A (ko) 2012-09-12
PE20050396A1 (es) 2005-07-05
HRP20100601B1 (hr) 2016-12-02
EP2316431A1 (en) 2011-05-04
IL170888A (en) 2010-06-16
CY2011013I2 (el) 2014-04-09
NO329332B1 (no) 2010-09-27
EP2008650A2 (en) 2008-12-31
CY1117071T1 (el) 2017-04-05
HUS1100016I1 (hu) 2016-08-29
RU2358716C2 (ru) 2009-06-20
GR1005052B (el) 2005-11-30
NO2011016I1 (no) 2011-09-19
AU2004228929B2 (en) 2008-02-07
BRPI0409250B8 (pt) 2022-01-18
AT504853A2 (de) 2008-08-15
AU2004228929A1 (en) 2004-10-21
RU2475237C2 (ru) 2013-02-20
BRPI0409250A (pt) 2006-03-28
AR078782A2 (es) 2011-11-30
AT501681B1 (de) 2012-04-15
US20140011885A1 (en) 2014-01-09
PE20131352A1 (es) 2013-11-14
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
AR078781A2 (es) 2011-11-30
EP1613288A1 (en) 2006-01-11
HK1091114A1 (en) 2007-01-12
ES2320767T3 (es) 2009-05-28
CY1110260T1 (el) 2014-04-09
IL197578A (en) 2015-10-29
IS2682B (is) 2010-10-15
KR20110005320A (ko) 2011-01-17
ECSP056090A (es) 2006-03-01
EP1613288B1 (en) 2008-11-19
RU2010147000A (ru) 2012-08-10
ITMI20040682A1 (it) 2004-07-06
RU2009105403A (ru) 2010-08-27
AR043987A1 (es) 2005-08-17
HUE028247T2 (en) 2016-12-28
IS8885A (is) 2010-02-25
US20190175527A1 (en) 2019-06-13
TW200503784A (en) 2005-02-01
FR2854073B1 (fr) 2008-03-14
DE602004017847D1 (de) 2009-01-02
IS8114A (is) 2005-11-01
IE20040246A1 (en) 2004-12-15
US20170290787A1 (en) 2017-10-12
JP5495467B2 (ja) 2014-05-21
FR11C0036I1 (fr) 2011-10-14
ES2228282A1 (es) 2005-04-01
PE20150676A1 (es) 2015-05-17
CN1767819B (zh) 2010-07-28
CN101797241A (zh) 2010-08-11
ES2556947T3 (es) 2016-01-21
MXPA05010860A (es) 2006-05-25
GB2400318B (en) 2005-08-10
CA2521325A1 (en) 2004-10-21
GB2400318A (en) 2004-10-13
SI1613288T1 (sl) 2009-04-30
HK1071685A1 (en) 2005-07-29
LU91867I2 (fr) 2011-11-08
PT1613288E (pt) 2009-02-25
SI2316431T1 (sl) 2016-04-29
NZ542622A (en) 2009-01-31
GB0407819D0 (en) 2004-05-12
TWI332847B (en) 2010-11-11
NO20055231D0 (no) 2005-11-07
CL2004000745A1 (es) 2005-02-11
NZ592339A (en) 2012-09-28
PE20130200A1 (es) 2013-03-09
EP2769713A1 (en) 2014-08-27
HRP20100600A2 (hr) 2011-03-31
IL242037A0 (en) 2015-11-30
RU2012148593A (ru) 2014-05-20

Similar Documents

Publication Publication Date Title
CN101797241B (zh) 包含s1p受体激动剂和糖醇的固体药物组合物
HK1091114B (en) Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
HK1155650A (en) Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
AU2008200368A1 (en) Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
HK1155647B (en) Solid oral composition comprising a s1p receptor agonist and a sugar alcohol

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: TANABE SEIYAKU CO. LTD.

Free format text: FORMER OWNER: MITSUBISHI PHARMACEUTICAL CO LTD

Effective date: 20130711

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: Basel, Switzerland

Patentee after: NOVARTIS AG

Patentee after: MITSUBISHI TANABE PHARMA Corp.

Address before: Basel, Switzerland

Patentee before: Novartis AG

Patentee before: Tanabe Seiyaku Co.,Ltd.

TR01 Transfer of patent right

Effective date of registration: 20130711

Address after: Basel, Switzerland

Patentee after: NOVARTIS AG

Patentee after: Tanabe Seiyaku Co.,Ltd.

Address before: Basel, Switzerland

Patentee before: Novartis AG

Patentee before: MITSUBISHI PHARMA Corp.

C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel, Switzerland

Patentee after: NOVARTIS AG

Patentee after: MITSUBISHI TANABE PHARMA Corp.

Address before: Basel, Switzerland

Patentee before: Novartis AG

Patentee before: MITSUBISHI TANABE PHARMA Corp.

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20130327